UPDATE: RBC Capital On Allogene Price Target Cut: Firm Warns On FDA Hold Following Detection Of Chromosomal Abnormality Following Clinical Trials; Sees Multiple Confounding Factors Given Current Findings Still Present Minimal To No Clinical Significance